Published in Physician Law Weekly, February 1st, 2006
"A multicenter, double-blind, placebo-controlled study was conducted to assess the efficacy and safety of fasudil, a Rhokinase inhibitor (RKI), in the treatment of acute ischemic stroke," scientists in Japan wrote.
"A total of 160 patients, who were able to receive drug treatment within 48 h of acute ischemic stroke onset were enrolled," wrote M. Shibuya and colleagues, Asahi Kasei Pharma Corporation.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly